<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03354598</url>
  </required_header>
  <id_info>
    <org_study_id>IT001-301</org_study_id>
    <nct_id>NCT03354598</nct_id>
  </id_info>
  <brief_title>Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women</brief_title>
  <official_title>A Prospective Phase 3 Randomized Multi-center Double-blind Study of Efficacy Tolerability &amp; Safety of Oral Sulopenem-etzadroxil/Probenecid vs Ciprofloxacin for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iterum Therapeutics, International Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iterum Therapeutics, International Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy,&#xD;
      tolerability, and safety of oral sulopenem-etzadroxil/probenecid versus oral ciprofloxacin&#xD;
      for treatment of uncomplicated urinary tract infection (uUTI) in adult women&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 16, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success</measure>
    <time_frame>Day 12+/-1 day</time_frame>
    <description>Overall Success: Clinical Success (resolution of uncomplicated urinary tract infection (uUTI) symptoms present at study entry and no new symptoms) AND Microbiologic success (eradication of the baseline pathogen)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Overall Success</measure>
    <time_frame>Day 12 +/- 1 day</time_frame>
    <description>Overall Success is Clinical Success (resolution of uUTI symptoms present at study entry and no new uUTI symptoms) AND Microbiologic success (eradication of the baseline pathogen)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Patients With Microbiologic Success</measure>
    <time_frame>Day 12+/-1 day</time_frame>
    <description>Microbiologic success is defined as eradication of the baseline pathogen (&lt;1000 Colony Forming Units (CFU)/mL) at the Test of Cure visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Microbiologic Modified Intent to Treat (Micro-MITT) Participants With Overall Success</measure>
    <time_frame>12 +/- 1 day</time_frame>
    <description>Overall Success is Clinical Success (resolution of uUTI symptoms present at study entry and no new uUTI symptoms) AND Microbiologic success (eradication of the baseline pathogen)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1671</enrollment>
  <condition>Uncomplicated Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Sulopenem-etzadroxil/probenecid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprofloxacin 250 mg PO administered twice daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulopenem-Etzadroxil/Probenecid</intervention_name>
    <description>Treatment of uncomplicated urinary tract infection</description>
    <arm_group_label>Sulopenem-etzadroxil/probenecid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Treatment of uncomplicated urinary tract infection</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients ≥18 years of age with 24-96 hours of urinary symptoms attributable to&#xD;
             a urinary tract infection (UTI)&#xD;
&#xD;
          2. Two of the following signs and symptoms of uUTI: urinary frequency, urinary urgency,&#xD;
             pain or burning micturition, suprapubic pain&#xD;
&#xD;
          3. A mid-stream urine specimen with:&#xD;
&#xD;
               1. a dipstick analysis positive for nitrite AND&#xD;
&#xD;
               2. evidence of pyuria as defined by either:&#xD;
&#xD;
             i. a dipstick analysis positive for leukocyte esterase ii. at least 10 white blood&#xD;
             cells per cubic millimeter on microscopic analysis of unspun urine iii. White blood&#xD;
             cell count ≥10 cells/high-powered field in the sediment of a spun urine&#xD;
&#xD;
          4. Has given written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of signs and symptoms suggestive of acute pyelonephritis: fever (temperature&#xD;
             &gt; 38°Celsius), chills, costovertebral angle tenderness, flank pain, nausea, and/or&#xD;
             vomiting&#xD;
&#xD;
          2. Receipt of antibacterial drug therapy potentially effective as treatment of uUTI&#xD;
             within the prior 7 days&#xD;
&#xD;
          3. Concurrent use of non-study treatments that would have a potential effect on outcome&#xD;
             evaluations in patients with uUTI&#xD;
&#xD;
          4. Patients with ileal loops or urinary stoma&#xD;
&#xD;
          5. Patients with an indwelling urinary catheter in the previous 30 days&#xD;
&#xD;
          6. Patients with paraplegia&#xD;
&#xD;
          7. Patients who are likely to receive ongoing antibacterial drug prophylaxis after&#xD;
             treatment of uUTI (e.g., patients with vesico-ureteral reflux)&#xD;
&#xD;
          8. Any history of trauma to the pelvis or urinary tract&#xD;
&#xD;
          9. Patient's urine culture, if available at study entry, identify more than 2&#xD;
             microorganisms regardless of colony count or patient has a confirmed fungal UTI&#xD;
&#xD;
         10. Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant&#xD;
&#xD;
         11. Known history of creatinine clearance &lt;50 mL/min&#xD;
&#xD;
         12. Patients known to have liver disease&#xD;
&#xD;
         13. Patients who are pregnant, or females of child-bearing age unable to take adequate&#xD;
             contraceptive precautions&#xD;
&#xD;
         14. Patients with uncontrolled diabetes mellitus&#xD;
&#xD;
         15. Patients with history of blood dyscrasias&#xD;
&#xD;
         16. Patients with history of uric acid kidney stones&#xD;
&#xD;
         17. Patients with acute gouty attack&#xD;
&#xD;
         18. Patients on chronic methotrexate therapy&#xD;
&#xD;
         19. Patient known to be immunocompromised&#xD;
&#xD;
         20. Patients with a known history of myasthenia gravis&#xD;
&#xD;
         21. Patients who require concomitant administration of tizanidine or valproic acid&#xD;
&#xD;
         22. Patients with a history of allergy or hypersensitivity to carbapenems, beta-lactams,&#xD;
             quinolones or probenecid&#xD;
&#xD;
         23. Patient is considered unlikely to survive the 4-week study period or has a rapidly&#xD;
             progressive or terminal illness including septic shock which is associated with a high&#xD;
             risk of mortality&#xD;
&#xD;
         24. History of seizures&#xD;
&#xD;
         25. Use of any other investigational drug in the 30 days prior to the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only females are eligible for this study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tolleson</city>
        <state>Arizona</state>
        <zip>85353</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Perry</city>
        <state>Georgia</state>
        <zip>31069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Hugo</city>
        <state>Oklahoma</state>
        <zip>74743</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <zip>29720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <results_first_submitted>November 20, 2020</results_first_submitted>
  <results_first_submitted_qc>November 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03354598/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03354598/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sulopenem-etzadroxil/Probenecid</title>
          <description>Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days&#xD;
Sulopenem-Etzadroxil/Probenecid: Treatment of uncomplicated urinary tract infection</description>
        </group>
        <group group_id="P2">
          <title>Ciprofloxacin</title>
          <description>Ciprofloxacin 250 mg PO administered twice daily for 3 days&#xD;
Ciprofloxacin: Treatment of uncomplicated urinary tract infection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="835"/>
                <participants group_id="P2" count="836"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants</title>
              <participants_list>
                <participants group_id="P1" count="370"/>
                <participants group_id="P2" count="415"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Microbiologic Modified Intent to Treat (Micro-MITT) Participants</title>
              <participants_list>
                <participants group_id="P1" count="517"/>
                <participants group_id="P2" count="554"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent to Treat (MITT) Participants</title>
              <participants_list>
                <participants group_id="P1" count="785"/>
                <participants group_id="P2" count="794"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat (ITT) Participants</title>
              <participants_list>
                <participants group_id="P1" count="787"/>
                <participants group_id="P2" count="803"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Participants</title>
              <participants_list>
                <participants group_id="P1" count="833"/>
                <participants group_id="P2" count="827"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="755"/>
                <participants group_id="P2" count="761"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat (ITT) Participants</population>
      <group_list>
        <group group_id="B1">
          <title>Sulopenem-etzadroxil/Probenecid</title>
          <description>Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days&#xD;
Sulopenem-Etzadroxil/Probenecid: Treatment of uncomplicated urinary tract infection</description>
        </group>
        <group group_id="B2">
          <title>Ciprofloxacin</title>
          <description>Ciprofloxacin 250 mg PO administered twice daily for 3 days&#xD;
Ciprofloxacin: Treatment of uncomplicated urinary tract infection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="787"/>
            <count group_id="B2" value="803"/>
            <count group_id="B3" value="1590"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="18.8"/>
                    <measurement group_id="B2" value="50.0" spread="19.1"/>
                    <measurement group_id="B3" value="49.9" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="787"/>
                    <measurement group_id="B2" value="803"/>
                    <measurement group_id="B3" value="1590"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="485"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="529"/>
                    <measurement group_id="B2" value="570"/>
                    <measurement group_id="B3" value="1099"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="448"/>
                    <measurement group_id="B2" value="441"/>
                    <measurement group_id="B3" value="889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success</title>
        <description>Overall Success: Clinical Success (resolution of uncomplicated urinary tract infection (uUTI) symptoms present at study entry and no new symptoms) AND Microbiologic success (eradication of the baseline pathogen)</description>
        <time_frame>Day 12+/-1 day</time_frame>
        <population>micro-MITTR population: patients with baseline uropathogen non-susceptible to the comparator ciprofloxacin.</population>
        <group_list>
          <group group_id="O1">
            <title>Sulopenem-etzadroxil/Probenecid</title>
            <description>Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days&#xD;
Sulopenem-Etzadroxil/Probenecid: Treatment of uncomplicated urinary tract infection</description>
          </group>
          <group group_id="O2">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin 250 mg PO administered twice daily for 3 days&#xD;
Ciprofloxacin: Treatment of uncomplicated urinary tract infection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success</title>
          <description>Overall Success: Clinical Success (resolution of uncomplicated urinary tract infection (uUTI) symptoms present at study entry and no new symptoms) AND Microbiologic success (eradication of the baseline pathogen)</description>
          <population>micro-MITTR population: patients with baseline uropathogen non-susceptible to the comparator ciprofloxacin.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6"/>
                    <measurement group_id="O2" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Overall Success</title>
        <description>Overall Success is Clinical Success (resolution of uUTI symptoms present at study entry and no new uUTI symptoms) AND Microbiologic success (eradication of the baseline pathogen)</description>
        <time_frame>Day 12 +/- 1 day</time_frame>
        <population>micro-MITTS population: patients with baseline uropathogen susceptible to the comparator ciprofloxacin.</population>
        <group_list>
          <group group_id="O1">
            <title>Sulopenem-etzadroxil/Probenecid</title>
            <description>Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days&#xD;
Sulopenem-Etzadroxil/Probenecid: Treatment of uncomplicated urinary tract infection</description>
          </group>
          <group group_id="O2">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin 250 mg PO administered twice daily for 3 days&#xD;
Ciprofloxacin: Treatment of uncomplicated urinary tract infection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Overall Success</title>
          <description>Overall Success is Clinical Success (resolution of uUTI symptoms present at study entry and no new uUTI symptoms) AND Microbiologic success (eradication of the baseline pathogen)</description>
          <population>micro-MITTS population: patients with baseline uropathogen susceptible to the comparator ciprofloxacin.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8"/>
                    <measurement group_id="O2" value="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Patients With Microbiologic Success</title>
        <description>Microbiologic success is defined as eradication of the baseline pathogen (&lt;1000 Colony Forming Units (CFU)/mL) at the Test of Cure visit</description>
        <time_frame>Day 12+/-1 day</time_frame>
        <population>micro-MITTR population: patients with baseline uropathogen non-susceptible to the comparator ciprofloxacin.</population>
        <group_list>
          <group group_id="O1">
            <title>Sulopenem-etzadroxil/Probenecid</title>
            <description>Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days&#xD;
Sulopenem-Etzadroxil/Probenecid: Treatment of uncomplicated urinary tract infection</description>
          </group>
          <group group_id="O2">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin 250 mg PO administered twice daily for 3 days&#xD;
Ciprofloxacin: Treatment of uncomplicated urinary tract infection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Patients With Microbiologic Success</title>
          <description>Microbiologic success is defined as eradication of the baseline pathogen (&lt;1000 Colony Forming Units (CFU)/mL) at the Test of Cure visit</description>
          <population>micro-MITTR population: patients with baseline uropathogen non-susceptible to the comparator ciprofloxacin.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1"/>
                    <measurement group_id="O2" value="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Microbiologic Modified Intent to Treat (Micro-MITT) Participants With Overall Success</title>
        <description>Overall Success is Clinical Success (resolution of uUTI symptoms present at study entry and no new uUTI symptoms) AND Microbiologic success (eradication of the baseline pathogen)</description>
        <time_frame>12 +/- 1 day</time_frame>
        <population>micro-MITT population: micro-MITTR and micro-MITTS (ciprofloxacin nonsusceptible and ciprofloxacin susceptible) populations combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Sulopenem-etzadroxil/Probenecid</title>
            <description>Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days&#xD;
Sulopenem-Etzadroxil/Probenecid: Treatment of uncomplicated urinary tract infection</description>
          </group>
          <group group_id="O2">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin 250 mg PO administered twice daily for 3 days&#xD;
Ciprofloxacin: Treatment of uncomplicated urinary tract infection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Microbiologic Modified Intent to Treat (Micro-MITT) Participants With Overall Success</title>
          <description>Overall Success is Clinical Success (resolution of uUTI symptoms present at study entry and no new uUTI symptoms) AND Microbiologic success (eradication of the baseline pathogen)</description>
          <population>micro-MITT population: micro-MITTR and micro-MITTS (ciprofloxacin nonsusceptible and ciprofloxacin susceptible) populations combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6"/>
                    <measurement group_id="O2" value="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of informed consent through the final visit, an average of 28 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sulopenem-etzadroxil/Probenecid</title>
          <description>Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days&#xD;
Sulopenem-Etzadroxil/Probenecid: Treatment of uncomplicated urinary tract infection</description>
        </group>
        <group group_id="E2">
          <title>Ciprofloxacin</title>
          <description>Ciprofloxacin 250 mg PO administered twice daily for 3 days&#xD;
Ciprofloxacin: Treatment of uncomplicated urinary tract infection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="833"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="833"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="833"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="833"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>small intestine obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="833"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="833"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="833"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="833"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="833"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="833"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="833"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>presuncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="833"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="833"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="833"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="947" subjects_affected="103" subjects_at_risk="833"/>
                <counts group_id="E2" events="91" subjects_affected="21" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI will provide Iterum opportunity to review proposed publication/other type of disclosure before submitted/disclosed. PI will provide full text of intended disclosure to Iterum at least 30 days before submitted/disclosed. If any patent action is required to protect intellectual property rights, PI agrees to delay disclosure for a period not to exceed an additional 60 days. PI will, on request, remove previously undisclosed Confidential Information before disclosure.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical Development</name_or_title>
      <organization>Iterum Therapeutics</organization>
      <phone>18606614035</phone>
      <email>saronin@iterumtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

